CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product in the Treatment of Relapsed/Refractory B-cell Malignancies
Epistemonikos ID: 4cc11db69f33136c4e69b5f5ce658810eac7ac4e
First added on: Aug 14, 2026